Exagen (XGN) Liabilities and Shareholders Equity (2018 - 2026)

Exagen (XGN) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $52.0 million the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $52.0 million, up 28.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $231.6 million (up 30.17% YoY), and the FY2025 annual result was $58.0 million, up 29.84% from the prior year.
• Liabilities and Shareholders Equity was $52.0 million for Q1 2026 at Exagen, down from $58.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $122.0 million in Q1 2022 and troughed at $40.3 million in Q1 2025.
• Average Liabilities and Shareholders Equity over 5 years is $67.0 million, with a median of $58.8 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity tumbled 40.03% in 2023 and soared 44.07% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $86.2 million in 2022, then plunged by 33.96% to $56.9 million in 2023, then dropped by 21.52% to $44.7 million in 2024, then advanced by 29.84% to $58.0 million in 2025, then dropped by 10.45% to $52.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $52.0 million in Q1 2026, $58.0 million in Q4 2025, and $62.8 million in Q3 2025.